Personal information

Emails & domains

Verified email domains

Activities

Collapse all

Works (25)

Long-term follow-up of Total Therapy IV: a phase 3 clinical trial for standard-risk multiple myeloma

Blood Advances
2025-02-25 | Journal article
DOI: 10.1182/bloodadvances.2024014889
Contributors: Samer Al Hadidi; Obada Ababneh; Carolina Schinke; Sharmilan Thanendrarajan; Clyde Bailey; Robert Smith; Susan Panozzo; Daisy Alapat; Guido Tricot; John Shaughnessy, Jr. et al.
Source: check_circle
Crossref

Prior Exposure to Belantamab Mafodotin Influences Outcomes with Idecabtagene Vicluecel in Patients with Multiple Myeloma

Blood Advances
2025-02-12 | Journal article
DOI: 10.1182/bloodadvances.2024015648
Contributors: Bhavesh Mohan Lal; Marah Alzubi; Jawad Alrawabdeh; John D. Shaughnessy, Jr; Fenghuang Zhan; Eric R Siegel; Carolina Schinke; Sharmilan Thanendrarajan; Maurizio Zangari; Frits van Rhee et al.
Source: check_circle
Crossref

Second primary malignancies after tandem autologous hematopoietic stem cell transplantation for multiple myeloma

American Journal of Hematology
2024-11 | Journal article
DOI: 10.1002/ajh.27452
Contributors: Samer Al Hadidi; Obada Ababneh; Carolina Schinke; Sharmilan Thanendrarajan; Clyde Bailey; Guido Tricot; John Shaughnessy, Jr; Fenghuang Zhan; Jeffrey Sawyer; Eric R. Siegel et al.
Source: check_circle
Crossref

Real-world experience with clinical management of talquetamab in relapsed/refractory multiple myeloma: a qualitative study of US healthcare providers

Current Medical Research and Opinion
2024-10-02 | Journal article
DOI: 10.1080/03007995.2024.2387183
Contributors: Carolina Schinke; Binod Dhakal; Sandra Mazzoni; Samantha Shenoy; Sara A. Scott; Tiffany Richards; Hoa H. Le; Amalia DeBrosse; Peter Okorozo; Rachel McDowell et al.
Source: check_circle
Crossref

Sustained remission following finite duration bispecific antibody therapy in patients with relapsed/refractory myeloma

Blood Cancer Journal
2024-08-12 | Journal article
DOI: 10.1038/s41408-024-01114-7
Contributors: Rajshekhar Chakraborty; Heloise Cheruvalath; Anannya Patwari; Aniko Szabo; Carolina Schinke; Binod Dhakal; Suzanne Lentzsch; Anita D’Souza; Ghulam Rehman Mohyuddin; Kelley Julian et al.
Source: check_circle
Crossref

A Risk Stratification System in Myeloma Patients with Autologous Stem Cell Transplantation

Cancers
2024-03 | Journal article | Author
DOI: 10.3390/cancers16061116
Contributors: Wancheng Guo; Christopher Strouse; David Mery; Eric Siegel; Manit N. Munshi; Timothy Cody Ashby; Yan Cheng; Fumou Sun; Visanu Wanchai; Zijun Zhang et al.
Source: check_circle
Multidisciplinary Digital Publishing Institute

Adverse effects and non-relapse mortality of BCMA directed T cell therapies in multiple myeloma: an FAERS database study

Blood Cancer Journal
2024-03-05 | Journal article
DOI: 10.1038/s41408-024-01023-9
Contributors: Zimu Gong; Godsfavour Umoru; Jorge Monge; Nishi Shah; Ghulam Rehman Mohyuddin; Sabarinath Venniyil Radhakrishnan; Rajshekhar Chakraborty; Leo Rasche; Carolina Schinke; Anita D’Souza et al.
Source: check_circle
Crossref

Three years of maintenance with VRD in multiple myeloma: results of total therapy IIIB with a 15-year follow-up

Blood Advances
2024-02-13 | Journal article
DOI: 10.1182/bloodadvances.2023011601
Contributors: Samer Al Hadidi; Obada Ehab Ababneh; Carolina D. Schinke; Sharmilan Thanendrarajan; Clyde Bailey; Robert Smith; Susan Panozzo; Daisy Alapat; Michele Cottler-Fox; Guido Tricot et al.
Source: check_circle
Crossref

BCMA- and CST6-specific CAR T cells lyse multiple myeloma cells and suppress murine osteolytic lesions

Journal of Clinical Investigation
2024-01-02 | Journal article
DOI: 10.1172/JCI171396
Contributors: Fumou Sun; Yan Cheng; Jin-Ran Chen; Visanu Wanchai; David E. Mery; Hongwei Xu; Dongzheng Gai; Samer Al Hadidi; Carolina Schinke; Sharmilan Thanendrarajan et al.
Source: check_circle
Crossref

EDNRA-Expressing Mesenchymal Cells Are Expanded in Myeloma Interstitial Bone Marrow and Associated with Disease Progression

Cancers
2023-09-12 | Journal article
DOI: 10.3390/cancers15184519
Contributors: Wen Ling; Sarah K Johnson; Syed J Mehdi; Daisy V Alapat; Michael Bauer; Maurizio Zangari; Carolina Schinke; Sharmilan Thanendrarajan; Frits van Rhee; Shmuel Yaccoby
Source: check_circle
Crossref
grade
Preferred source (of 2)‎

Resolving the spatial architecture of myeloma and its microenvironment at the single-cell level

Nature Communications
2023-08-17 | Journal article
DOI: 10.1038/s41467-023-40584-4
Contributors: Lukas John; Alexandra M. Poos; Alexander Brobeil; Carolina Schinke; Stefanie Huhn; Nina Prokoph; Raphael Lutz; Barbara Wagner; Maurizio Zangari; Stephan M. Tirier et al.
Source: check_circle
Crossref

Risk of infections associated with the use of bispecific antibodies in multiple myeloma: a pooled analysis

Blood Advances
2023-07-11 | Journal article
DOI: 10.1182/bloodadvances.2022009435
Contributors: Farah Mazahreh; Liyan Mazahreh; Carolina Schinke; Sharmilan Thanendrarajan; Maurizio Zangari; John D. Shaughnessy, Jr.; Fenghuang Zhan; Frits van Rhee; Samer Al Hadidi
Source: check_circle
Crossref

Characterizing the role of the immune microenvironment in multiple myeloma progression at a single-cell level

Blood Advances
2022-11-22 | Journal article
DOI: 10.1182/bloodadvances.2022007217
Contributors: Carolina Schinke; Alexandra M. Poos; Michael Bauer; Lukas John; Sarah Johnson; Shayu Deshpande; Luis Carrillo; Daisy Alapat; Leo Rasche; Sharmilan Thanendrarajan et al.
Source: check_circle
Crossref

The spatio-temporal evolution of multiple myeloma from baseline to relapse-refractory states

Nature Communications
2022-08-03 | Journal article
DOI: 10.1038/s41467-022-32145-y
Contributors: Leo Rasche; Carolina Schinke; Francesco Maura; Michael A. Bauer; Cody Ashby; Shayu Deshpande; Alexandra M. Poos; Maurizio Zangari; Sharmilan Thanendrarajan; Faith E. Davies et al.
Source: check_circle
Crossref

First‐ versus second‐generation Bruton tyrosine kinase inhibitors in Waldenström's Macroglobulinemia: A systematic review and meta‐analysis

American Journal of Hematology
2022-07 | Journal article
DOI: 10.1002/ajh.26552
Contributors: Hassan Abushukair; Sebawe Syaj; Obada Ababneh; Aref Qarqash; Carolina Schinke; Sharmilan Thanendrarajan; Maurizio Zangari; Frits van Rhee; Samer Al Hadidi
Source: check_circle
Crossref

Feasibility of Outpatient Stem Cell Transplantation in Multiple Myeloma and Risk Factors Predictive of Hospital Admission

Journal of Clinical Medicine
2022-03 | Journal article | Author
DOI: 10.3390/jcm11061640
Contributors: Kristin Larsen; Horace Spencer; Meera Mohan; Clyde Bailey; Kerri Hill; Mathew Kottarathara; Richa Parikh; Shadiqul Hoque; Amani Erra; Angel A. Mitma et al.
Source: check_circle
Multidisciplinary Digital Publishing Institute

The Spatio-Temporal Evolution of Multiple Myeloma from Baseline to Relapse-Refractory States

2022-01-21 | Preprint
DOI: 10.21203/rs.3.rs-1177985/v1
Contributors: Niels Weinhold; Leo Rasche; Carolina Schinke; Francesco Maura; Michael Bauer; Cody Ashby; Shayu Deshpande; Alexandra Poos; Maurizio Zangari; Sharmilan Thanendrarajan et al.
Source: check_circle
Crossref

Persistent bone marrow minimal residual disease as a “high‐risk” disease feature in multiple myeloma

American Journal of Hematology
2021-09 | Journal article
DOI: 10.1002/ajh.26255
Contributors: Meera Mohan; Aniko Szabo; Naveen Yarlagadda; Sravani Gundarlapalli; Sharmilan Thanendrarajan; Samantha Kendrick; Carolina Schinke; Daisy Alapat; Jeffrey Sawyer; Erming Tian et al.
Source: check_circle
Crossref

The Role of Monoclonal Antibodies in the Era of Bi-Specifics Antibodies and CAR T Cell Therapy in Multiple Myeloma

Cancers
2021-09 | Journal article | Author
DOI: 10.3390/cancers13194909
Contributors: Meera Mohan; Theresa Camille Maatman; Carolina Schinke
Source: check_circle
Multidisciplinary Digital Publishing Institute
grade
Preferred source (of 2)‎

Salvage Autologous Stem Cell Transplantation in Daratumumab-Refractory Multiple Myeloma

Cancers
2021-08 | Journal article | Author
DOI: 10.3390/cancers13164019
Contributors: Lakshmi Yarlagadda; Sravani Gundarlapalli; Richa Parikh; Reid Landes; Mathew Kottarathara; Yetunde Ogunsesan; Shadiqul Hoque; Angel A. Mitma; Clyde Bailey; Kerri M. Hill et al.
Source: check_circle
Multidisciplinary Digital Publishing Institute

PHF19 inhibition as a therapeutic target in multiple myeloma

Current Research in Translational Medicine
2021-07 | Journal article
DOI: 10.1016/j.retram.2021.103290
Contributors: Carolina D. Schinke; Jordan T. Bird; Pingping Qu; Shmuel Yaccoby; Valeriy V. Lyzogubov; Randal Shelton; Wen Ling; Eileen M. Boyle; Sharyu Deshpande; Stephanie D. Byrum et al.
Source: check_circle
Crossref

Clinical characteristics of testicular extramedullary involvement in multiple myeloma

American Journal of Hematology
2021-03 | Journal article
DOI: 10.1002/ajh.26072
Contributors: Meera Mohan; Naveen Yarlagadda; Aniko Szabo; Amrit Singh; Sergio Pina Oviedo; Carolina Schinke
Source: check_circle
Crossref

Monitoring treatment response and disease progression in myeloma with circulating cell‐free DNA

European Journal of Haematology
2021-02 | Journal article
DOI: 10.1111/ejh.13541
Contributors: Shayu Deshpande; Ruslana G. Tytarenko; Yan Wang; Eileen M. Boyle; Cody Ashby; Carolina D. Schinke; Sharmilan Thanendrarajan; Maurizio Zangari; Fenghuang Zhan; Faith E. Davies et al.
Source: check_circle
Crossref

Genomic analysis of primary plasma cell leukemia reveals complex structural alterations and high-risk mutational patterns

Blood Cancer Journal
2020-06-19 | Journal article
DOI: 10.1038/s41408-020-0336-z
Contributors: Carolina Schinke; Eileen M. Boyle; Cody Ashby; Yan Wang; Valeriy Lyzogubov; Christopher Wardell; Pingping Qu; Antje Hoering; Shayu Deshpande; Katie Ryan et al.
Source: check_circle
Crossref

Multiple Myeloma DREAM Challenge Reveals Epigenetic RegulatorPHF19As Marker of Aggressive Disease

2019-08-22 | Preprint
DOI: 10.1101/737122
Contributors: Mike J Mason; Carolina Schinke; Christine L P Eng; Fadi Towfic; Fred Gruber; Andrew Dervan; Brian S White; Aditya Pratapa; Yuanfang Guan; Hongjie Chen et al.
Source: check_circle
Crossref
How many people are using ORCID?